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Background. The prevalence of peripheral vascular disease has led to the re-emergence of percutaneous axillary vascular access as a
suitable alternative access site to femoral artery. We sought to investigate the eﬃcacy and safety of manual hemostasis in the axillary
artery. Methods. Data were collected from a prospective internal registry of patients who had a Maquet (Rastatt, Germany) Mega 50 cc
intra-aortic balloon pumps (IABP) placed in the axillary artery position. They were anticoagulated with weight-based intravenous
heparin to maintain an activated partial thromboplastin time (aPTT) of 50–80 seconds. Anticoagulation was discontinued 2 hours
prior to the device explantation. Manual compression was used to achieve the hemostasis of the axillary artery. Vascular and bleeding
complications attributable to manual hemostasis were classiﬁed based on the Valve Academic Research Consortium-2 (VARC-2) and
Bleeding Academic Research Consortium-2 (BARC-2) classiﬁcations, respectively. Results. 29 of 46 patients (63%) achieved axillary
artery homeostasis via manual compression. The median duration of IABP implantation was 12 days (range 1–54 days). Median
compression time was 20 minutes (range 5–60 minutes). There were no major vascular or bleeding complications as deﬁned by the
VARC-2 and BARC-2 criteria, respectively. Conclusion. Manual compression of the axillary artery appears to be an eﬀective and safe
method for achieving hemostasis. Large prospective randomized control trials may be needed to corroborate these ﬁndings.
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1. Introduction
The femoral artery remains the vascular access site of choice
for endovascular procedures requiring large bore arterial
access (LBA) including complex coronary intervention,
mechanical circulatory support (MCS), endovascular aortic
aneurysm repairs (EVAR), and transcatheter aortic valve
replacement (TAVR). Both peripheral vascular disease
(PVD) and coronary artery disease (CAD) have similar risk
factors, and it is common to encounter the challenge of
treating structural or complex coronary disease in patients
with signiﬁcant concomitant PAD. Several studies have

shown the overall prevalence of PAD in patients undergoing
TAVR of about 25%, with outcomes associated with a
traditional femoral approach known to be worse in this
population [1, 2].
Percutaneous axillary vascular access has recently reemerged as an alternative percutaneous access option for
large bore arteriotomies in patients with severe or occlusive
iliofemoral vascular disease and in fact has now become the
most utilized alternative access technique in the United
States. However, safe axillary vascular access with eﬀective
hemostasis requires special techniques which have not been
well described in the literature. The eﬃcacy of manual
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hemostasis for axillary vascular access is unknown. Therefore, we sought to investigate the use and outcomes of
manual hemostasis in the axillary artery for the removal of
percutaneously inserted intra-aortic balloon pumps
(IABPs).

2. Methods
Data were collected from a prospective internal registry of
patients who had a Maquet (Rastatt, Germany) 8-French
Mega 50 cc IABP placed in the axillary artery position in 46
consecutive patients [3]. A majority of these devices were
placed for acute decompensated congestive heart failure
deemed to require mechanical circulatory support based on
hemodynamic indices and used as a bridge to recovery or
destination therapy. The registry included comprehensive
data related to the insertion and removal of the device. All
the devices were inserted in the cardiac catheterization lab
using our previously described techniques for percutaneous
axillary access and performed using a combination of palpation, vascular ultrasound, and angiographic visualization
[4].
Following device insertion, the patients were most frequently supported with 1 : 1 counter pulsation, and, per our
group’s standardized strategy, anticoagulated with a 50 U/kg
weight-based bolus of heparin and subsequently started on a
weight-based drip to maintain an activated partial thromboplastin time (aPTT) of 50–80 seconds for the duration of
device of implantation.
Prior to device removal, all patients were assessed for
their ability to tolerate weaning of MCS with trials of 1 : 2
and 1 : 3 augmentation. If weaning was tolerated, 1 : 1 augmentation was resumed and anticoagulation discontinued
for 2 hours prior to device removal. aPTTs were not routinely assessed prior to the device removal. Patients were
brought back to the catheterization lab if their ability to
tolerate MCS weaning was uncertain and re-insertion or
exchange of MCS device was felt to be a possibility. Otherwise, IABPs were removed at bedside in the Cardiac
Critical Care Unit.
We analyzed the methods for achieving hemostasis of
the axillary artery at time of IABP removal. Vascular and
bleeding complications attributable to manual hemostasis
were classiﬁed based on the Valve Academic Research
Consortium-2 (VARC-2) and Bleeding Academic Research
Consortium-2 (BARC-2) classiﬁcations, respectively. Additionally, any neurologic complications related to manual
compression and hemostasis, mainly brachial plexopathies,
were evaluated.

®

3. Results
3.1. Study Population. Of the 46 patients who had an IABP
placed in the axillary artery, manual compression for hemostasis was used in 29 patients (63%). The remaining
patients had the catheter removed with a variety of techniques including closure device (Angio-Seal) or balloon
tamponade. No further information is available for these
cases. All catheters were placed in the left axillary artery.

Baseline characteristics (Table 1) for those patients in whom
manual compression was used for hemostasis showed an
average age of 55.9 years (range 21–74 years) and a predominance of males (21/29, 72.4). Signiﬁcant comorbidities
included coronary artery disease (3/29, 10.3%), diabetes
mellitus (6/29, 20.7%), and chronic kidney disease (11/29,
37.9%). The median LVEF by echocardiography was 19%
(range 10–55%). The average BMI was 29.5 kg/m2 (range
18–59 kg/m2). All patients ambulated, while the IABP was in
place (29/29, 100%). The median duration of IABP implantation was 12 days (range 1–54 days). Hemostasis was
achieved at bedside in 19/29 patients (65.5%). Median
compression time was 20 minutes (range 5–60 minutes).
3.2. Removal Technique. In each case, the IABP console was
placed on “standby” mode to fully extract helium from the
catheter. Next, the skin site of entry was sterilely scrubbed
with caution, and then sutures holding the catheter were cut
and removed. Manual pressure was exerted medially to the
entry site, and the catheter and any sheath were directly
removed after initially allowing some bleedback (<10 cc
blood). Pressure was exerted while observing the arteriotomy site lateral to the compression to assure no bleeding
was noted. Fifteen minutes of occlusive pressure was applied,
and then progressive reduction of pressure over 5 minutes
until pressure was discontinued.
3.3. Safety Outcomes. In the 29 patients in whom manual
compression was used to achieve hemostasis of the axillary
artery, there were no major vascular or bleeding complications as deﬁned by the VARC-2 and BARC-2 criteria,
respectively. Three (3/29, 10.3%) patients experienced a
minor vascular complication related to hemostasis, as deﬁned by the VARC-2 classiﬁcation. Three (3/29, 10.3%)
patients experienced a BARC-2 type 1 or type 2 bleeding
event. No patients required blood transfusions for bleeding
or intervention by vascular surgery. No brachial nerve plexus
injuries were experienced (Table 2). Additionally, there were
no site-related infections or clinically signiﬁcant cerebrovascular events following the IABP removal.

4. Discussion
Despite the use of newer access sites such as the radial artery
or axillary artery, common femoral artery access remains the
most commonly used site for access both in the United States
and worldwide. This is likely due to the familiarity in
obtaining access and achieving hemostasis at this site, which
is relatively unchanged since percutaneous access of the
femoral artery was ﬁrst introduced by Sven Seldinger in 1953
[5]. Hemostasis of the femoral artery is predicated on the
concept of compressibility against the underlying femoral
head. As such, the ideal site for femoral arterial puncture is
from the lower border of the head of the femur to the
midportion of the femoral head, known as the “target zone”
[6]. This site insures an area of compressibility with
avoidance of cannulation above the inguinal ligament or
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Table 1: Patient characteristics.
Characteristic
Manual Hemostasis (N � 29)
Age–years (range)
55.9 (21–74)
Male–no. (%)
21 (72.4)
Weight–kg (range)
87.5 (40–151.8)
29.5 (18–59)
BMI–kg/m2 (range)
Non-African American–no. (%)
26 (89.7)
African American–no. (%)
3 (10.3)
Diabetes mellitus–no. (%)
6 (20.7)
Coronary artery disease–no. (%)
3 (10.3)
Chronic kidney disease–no. (%)
11 (37.9)
LVEF-(%) (range)
19 (10–55)
Access left axillary artery–no. (%)
29 (100)
Ambulated–no. (%)
29 (100)
Median duration of
12 (1–54)
insertion–days (range)
Median compression time–min.
20 (5–60)
(Range)
Removal at bedside–no. (%)
19 (65.5)

Table 2: Safety outcomes.
Outcome
VARC-2 major–no. (%)
VARC-2 minor–no. (%)
BARC-2 type 3–5–no. (%)
BARC-2 type 1-2–no. (%)
Vascular surgery intervention–no. (%)
Bleeding requiring transfusion–no. (%)
Brachial plexus injury–no. (%)
Access site infection–no. (%)
Cerebrovascular accident–no. (%)

Event (N � 29)
0 (0)
3 (10.3)
0 (0)
3 (10.3)
0 (0)
0 (0)
0 (0)
0 (0)
0 (0)

below the femoral bifurcation which minimizes complications such as bleeding or hematoma formation.
Axillary artery access is not a new concept. It was
originally performed by palpation and cannulation of the
artery along the deltopectoral groove or within the true
axilla itself, with the arm typically abducted to 90 degrees
or positioned above the patient’s head. Access was initially performed at this site due to its proximity to the
humeral head after drawing on prior experiences seen
with traditional percutaneous femoral artery access.
Additionally, anatomic studies suggested that abduction
of the arm draws the axillary artery over the humeral
head, creating an additional point of possible compression much like access in the femoral artery. This was
described by Rohrer et al. who analyzed axillary artery
thrombosis in baseball pitchers and found that impingement of the third portion of the axillary artery by
the head of the humerus occurred in athletes, as well as
nonathletes, when the arm was placed in an abducted and
externally rotated position, such as would occur with a
baseball pitcher’s throwing motion [7].
Unfortunately, this technique was found to have an
overall complication rate as high as 24%, driven mostly by
brachial plexus injury and hematoma formation, which
eventually lead to its abandonment [8]. This unacceptably

high complication rate associated with early percutaneous transaxillary access performed in this manner was
largely attributable to the convergence of multiple brachial plexus elements in the area of access, as well as the
presence of the brachial fascial sheath which encompasses
the artery, vein, and nerve, wherein even minor bleeding
events may lead to a neurovascular compression
syndrome.
However, a recent resurgence in interest for percutaneous transaxillary access continues to grow with
outcomes on par with traditional percutaneous femoral
access aside from a few reports citing an elevated risk of
cerebrovascular accident associated with this approach.
This has, in large part, been due to data suggesting inferior
outcomes with surgical techniques requiring intrathoracic
access for transcatheter aortic valve replacements
(TAVRs) when transfemoral access is not suitable.
Schäfer et al. were among the ﬁrst to describe the
technique of percutaneous transaxillary artery access for
TAVR in a large case series format [9]. As opposed to
previous transaxillary access techniques, their technique
utilized an anterior approach through the chest wall,
entering the axillary artery in its ﬁrst segment, or in the
proximal 1/3 of the vessel. The advantage of this technique
includes, among other aspects, potential compressibility
of the vessel against the second rib for manual hemostasis,
if needed. As such, Schäfer et al. observed a signiﬁcantly
lower complication rate than was reported in the previous
studies [10].
In contradistinction to this, our technique for percutaneous transaxillary access has been directed towards
an access point in the middle third of the vessel, typically
referred to as the second portion, due to a well-deﬁned
paucity of brachial plexus elements associated with the
artery in this area [11]. Access in this area avoids the risk
of entering the intrathoracic cavity which may occur
while targeting the ﬁrst portion of the vessel and can
decrease the risk of additional complications, such as
hemo-or pneumothoraces, and facilitate surgical cut
down and bail out strategies if they were required.
Despite a lack of bony structures in this area to which
compression of the artery may be secured against, the
ﬁndings of our current study, as well as others, suggest
manual compression for hemostasis of the axillary artery
to be feasible and safe. It is important to note, however,
that a lack of bony structures in this area to facilitate
manual compression leads to potential displacement of
the vessel when attempting compression. As such, attention must be paid when securing hand placement and
stabilizing the vessel for manual hemostasis.
In many instances, urgency of device implantation or
uncertain duration of implantation deters many physicians from placement of vascular closure devices or from
using well described arteriotomy preclosure techniques.
This concern becomes further ampliﬁed in the cardiac
transplantation population as any form of infection or
vascular complication could delay the deﬁnitive therapy
in terms of transplant listing status or potentially increase
the risk of infection and, in turn, greater morbidity, given
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these complex patients require relatively aggressive immunosuppression immediately after transplantation.
More interestingly, our data may suggest signiﬁcant
clinical beneﬁt for the use of percutaneous axillary artery
implantation of MCS for prolonged support, given all
patients were ambulated and no patients experienced a
site-related infection, thus allowing for optimized patient
condition prior to transplantation or insertion of durable
LVAD. Moreover, no upper extremity ischemia was experienced which may relate to the fact that desired access
point in the second portion of the axillary artery is
proximal to the subscapularis artery which is known to
collateralize the brachial artery.
In our study, all 29 patients had successful hemostasis
of the axillary artery achieved with manual compression.
Three minor bleeding complications occurred, mainly
small chest wall hematomas, which resolved without
reintervention or blood transfusion. It should also be
noted that one patient utilized manual compression for
successful hemostasis after a failed vascular closure device. This suggests that manual hemostasis may oﬀer an
alternative to covered stent use as a bailout in certain
settings. Furthermore, manual hemostasis could obviate
the need for late use of vascular closure devices to achieve
hemostasis in patients with prolonged device implantations, thus reducing infection and complication risks.
The ﬁrst limitation of our study is that patients had
axillary artery access performed for the insertion of an
intra-aortic balloon pump. This device requires an 8French (Fr) arteriotomy, whether sheathed or sheathless,
and thus not a true “large bore” arteriotomy. This limits
the generalizability of this technique to other endovascular procedures utilizing the axillary artery access point.
However, our experience with manual hemostasis in the
IABP population has led us to develop an increased
comfort with utilizing manual compression to facilitate
hemostasis in large bore arteriotomies, even those requiring 14–16 Fr arteriotomies. A second limitation is the
lack of data available with regards to coagulation testing.
All patients were maintained on unfractionated heparin
utilizing a standard weight-based dosing while the IABP
was in place. Irrespective of aPTT, all IABPs were removed after 2 hours of heparin discontinuation. Fortunately, no major bleeding complications were observed. A
third limitation is that, in patients who underwent device
removal at bedside, angiography was not utilized to
conﬁrm the absence of upper extremity embolization or
thrombosis. Thus, it is possible that vascular events could
have been greater than observed, although clinically this
was not the case. Lastly, in contradistinction to recent
literature suggesting higher rates of CVA, we had no
events, and this may relate to the size of the device
utilized relative to the vessel size, operator experience, or
minute diﬀerences in procedural technique.
In conclusion, manual compression of the axillary
artery appears to be an eﬀective and safe method for
achieving hemostasis. Further studies may be needed to
corroborate these ﬁndings, especially in procedures requiring larger arteriotomies.
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